Respiratory Distress Syndrome (RDS) therapy developed in a non-invasive, aerosol delivery method
Respiratory distress syndrome (RDS) is a disease that occurs in premature newborns whose lungs have not completely developed. The primary cause of RDS is not enough surfactant in the lungs. The currently available methods to deliver surfactant replacement therapy utilize a wide range of methods that have varied levels of difficulty and impact on the patient. Conversely, treatment of RDS using aerosolized surfactant would provide a gentler approach to deliver therapy early in the course of the disease. Lovelace Biomedical recently worked with Windtree Therapeutics, Inc. (https://www.windtreetx.com/) to characterize the dose of lyophilized lucinactant delivered with the Aerosurf® Delivery System (Windtree) in nonhuman primates as a model for neonates (https://www.liebertpub.com/doi/10.1089/jamp.2018.1505). Noninvasive delivery of lucinactant as an aerosol resulted in homogenous delivery throughout the lungs. These results have contributed to the development of a potential alternative to other more invasive methods to deliver surfactant for the treatment of RDS in neonates.